Barbexaclone

Barbexaclone
Combination of
PhenobarbitalBarbiturate
LevopropylhexedrineSympathomimetic
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
  • BR: Class B1 (Psychoactive drugs)[1]
  • US: Schedule IV
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.022.278
 NY (what is this?)  (verify)

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[2] It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[3] had not yet been confirmed nor denied in controlled trials.

Potency

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[2]

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ a b Shorvon S, Perucca E, Engel Jr J (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
  3. ^ Salles Barbosa MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–249. doi:10.1590/s0004-282x1978000300009. PMID 28716.

Further reading

  • Shorvon SR, Fish DR, Perucca E, Dodson WE, eds. (2004). The Treatment of Epilepsy (2nd ed.). Published by Blackwell. p. 472. ISBN 0-632-06046-8.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.